Abstract
The present study investigates the specific drug targeting of anti retroviral drugs, such as lamivudine and zidovudine, after intraperitoneal (i.p) injection by incorporation into polymeric nanoparticles (PNs) and solid lipid nanoparticles (SLNs). Our results showed that Glyceryl Monosterate-Poloxamer 188 SLNs (average diameter of 522.466 nm) showed slow drug release rates (63.18% of lamivudine and 62.37% of zidovudine were released in 12 hrs) among all the SLN formulations. For Poly lactic-co-glycolic acid (PLGA)-Poloxamer 188 PNs (average diameter of 70.348 nm), there were faster release rates of both lamivudine and zidovudine (97% and 94.06%, respectively, in 12 hrs). Tissue distribution studies were carried out in mice and concentrations of drugs in different organs were determined using high performance liquid chromatography (HPLC) after i.p. administration. Glyceryl Monosterate-Poloxamer 188 SLNs and PLGAPoloxamer 188 PNs showed increase in the distribution of lamivudine and zidovudine to liver and spleen when compared to the drugs in solution. Also, Glyceryl Monosterate-P 188 SLNs showed higher concentration of drugs in RES organs than PLGA-P 188 PNs.
Keywords: Drug targeting, high performance liquid chromatography, Lamivudine, Zidovudine, nanoparticles, transdermal absorption, electrically neutral polymer, physicochemical properties.
Current Drug Delivery
Title:Comparative Studies of Lamivudine-zidovudine Nanoparticles for the Selective Uptake by Macrophages
Volume: 9 Issue: 5
Author(s): V. Sankar, Parmar Nilaykumar Nareshkumar, Gohel Nishit Ajitkumar, Shalini Devi Penmetsa and Sivaram Hariharan
Affiliation:
Keywords: Drug targeting, high performance liquid chromatography, Lamivudine, Zidovudine, nanoparticles, transdermal absorption, electrically neutral polymer, physicochemical properties.
Abstract: The present study investigates the specific drug targeting of anti retroviral drugs, such as lamivudine and zidovudine, after intraperitoneal (i.p) injection by incorporation into polymeric nanoparticles (PNs) and solid lipid nanoparticles (SLNs). Our results showed that Glyceryl Monosterate-Poloxamer 188 SLNs (average diameter of 522.466 nm) showed slow drug release rates (63.18% of lamivudine and 62.37% of zidovudine were released in 12 hrs) among all the SLN formulations. For Poly lactic-co-glycolic acid (PLGA)-Poloxamer 188 PNs (average diameter of 70.348 nm), there were faster release rates of both lamivudine and zidovudine (97% and 94.06%, respectively, in 12 hrs). Tissue distribution studies were carried out in mice and concentrations of drugs in different organs were determined using high performance liquid chromatography (HPLC) after i.p. administration. Glyceryl Monosterate-Poloxamer 188 SLNs and PLGAPoloxamer 188 PNs showed increase in the distribution of lamivudine and zidovudine to liver and spleen when compared to the drugs in solution. Also, Glyceryl Monosterate-P 188 SLNs showed higher concentration of drugs in RES organs than PLGA-P 188 PNs.
Export Options
About this article
Cite this article as:
Sankar V., Nilaykumar Nareshkumar Parmar, Nishit Ajitkumar Gohel, Devi Penmetsa Shalini and Hariharan Sivaram, Comparative Studies of Lamivudine-zidovudine Nanoparticles for the Selective Uptake by Macrophages, Current Drug Delivery 2012; 9 (5) . https://dx.doi.org/10.2174/156720112802650707
DOI https://dx.doi.org/10.2174/156720112802650707 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Structured Treatment Interruptions on Metabolic, Anthropometric, Immunologic, and Quality of Life Outcomes in HIV-Positive Adults on HAART
Current HIV Research The Role of Adipocytokines and Neurohormonal Dysregulation in Metabolic Syndrome
Current Diabetes Reviews GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
Current Drug Metabolism Role of Connexins and Pannexins in Ischemic Stroke
Current Medicinal Chemistry Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents Human Use of Leucoselect® Phytosome® with Special Reference to Inflammatory- Allergic Pathologies in Frail Elderly Patients
Current Pharmaceutical Design Calcium Channel Mutations in Cardiac Arrhythmia Syndromes
Current Molecular Pharmacology The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Hyperhomocysteinemia and Endothelial Dysfunction
Current Hypertension Reviews Heart Rate Variability Analysis at Coronary Artery Disease and Angina Pectoris
Recent Patents on Cardiovascular Drug Discovery Role of Ox-LDL and LOX-1 in Atherogenesis
Current Medicinal Chemistry Anti-Inflammatory, Gastrointestinal and Hepatoprotective Effects of Ocimum sanctum Linn: An Ancient Remedy with New Application
Inflammation & Allergy - Drug Targets (Discontinued) Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Prospects for Rational Development of Pharmacological Gap Junction Channel Blockers
Current Drug Targets Mediterranean Diet and Longevity
Current Nutrition & Food Science Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges
Current Drug Targets NF-κB Inhibition Resolves Cognitive Deficits in Experimental Type 2 Diabetes Mellitus through CREB and Glutamate/GABA Neurotransmitters Pathway
Current Neurovascular Research Vildagliptin Induces β-Cell Neogenesis and Improves the Lipid Profile in a Later Phase of Type 1 Diabetes
Current Pharmaceutical Biotechnology